Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person CALCR binds gepants

Class:IdReaction:9702849
_displayNameCALCR binds gepants
_doReleaseTRUE
_timestamp2022-05-10 17:55:00
authored[InstanceEdit:9702847] Jassal, Bijay, 2020-10-02
compartment[Compartment:984] extracellular region
[Compartment:876] plasma membrane
created[InstanceEdit:9702847] Jassal, Bijay, 2020-10-02
definitionAntagonist
edited[InstanceEdit:9702847] Jassal, Bijay, 2020-10-02
[InstanceEdit:9773839] Matthews, Lisa, 2022-05-10
input[EntityWithAccessionedSequence:419798] CALCR [plasma membrane] [Homo sapiens]
[CandidateSet:9702821] gepants [extracellular region]
isChimericFALSE
literatureReference[LiteratureReference:9702862] Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment
[LiteratureReference:9702812] Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries
[LiteratureReference:9702824] Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
[LiteratureReference:9702790] Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine
[LiteratureReference:9702840] Ubrogepant for the Treatment of Migraine
[LiteratureReference:9702868] Recent Advances in Pharmacotherapy for Episodic Migraine
modified[InstanceEdit:9702861] Jassal, Bijay, 2020-10-02
[InstanceEdit:9703824] Jassal, Bijay, 2020-10-07
[InstanceEdit:9773229] Matthews, Lisa, 2022-05-03
[InstanceEdit:9773839] Matthews, Lisa, 2022-05-10
[InstanceEdit:9773858] Matthews, Lisa, 2022-05-10
[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
nameCALCR binds gepants
output[Complex:9702814] CALCR:gepants [plasma membrane] [Homo sapiens]
releaseDate2022-06-09
reviewed[InstanceEdit:9767610] Huddart, Rachel, 2022-03-01
reviewStatus[ReviewStatus:9821382] five stars
species[Species:48887] Homo sapiens
stableIdentifier[StableIdentifier:9702860] R-HSA-9702849.2
summation[Summation:9702827] Migraine is the most common neurological disorder. First- an...
(hasEvent)[Pathway:419812] Calcitonin-like ligand receptors [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by CALCR binds gepants (9702849)